Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose-lowering agent: An analysis from VERTIS CV.
Samuel Dagogo-JackChristopher P CannonDavid Z I CherneyFrancesco CosentinoJie LiuAnnpey PongIra GantzRobert FrederichJames P MancusoRichard E PratleyPublished in: Diabetes, obesity & metabolism (2022)
gov identifier: NCT01986881.